EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial

Graham Roberts iD, Jocelyne Just iD, Hendrik Nolte, Ole Holm Hels iD, Andrzej Emeryk iD, Carmen Vidal iD

Allergy · 2025

DOI: 10.1111/all.70073 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Allergy, 2025. Verfasst von Graham Roberts und 5 weiteren Autor:innen. Beteiligte Einrichtung: The David Hide Asthma and Allergy Centre, St Mary's Hospital, Newport, Isle of Wight, UK. Hauptthemen laut MEDLINE: Asthma, Sublingual Immunotherapy, Pyroglyphidae, Antigens, Dermatophagoides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ALK-Abelló A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In children, house dust mite (HDM) sensitisation is a contributing factor for developing allergic asthma. HDM allergen immunotherapy has demonstrated efficacy and safety in adults with allergic asthma; however, evidence for its use in children is limited. MT‐11 evaluated the efficacy and safety of the SQ HDM sublingual immunotherapy (SLIT) tablet in children (5–17 years) with HDM allergic asthma.

Methods

This phase III, randomised, double‐blind, placebo‐controlled trial randomised 533 children with a recent history of asthma exacerbations, despite treatment with inhaled corticosteroids and/or long‐acting beta‐agonists, to daily treatment with SQ HDM SLIT‐tablet or placebo for 24–30 months. The primary endpoint was the annualised rate of clinically relevant asthma exacerbations. Adverse events (AEs) were reported throughout the trial.

Results

The rate ratio for the annualised rate of clinically relevant asthma exacerbations was 0.89 (95% CI: 0.60, 1.31), in favour of the SQ HDM‐SLIT tablet; superiority over placebo was not established. Most treatment‐related AEs (TRAEs) were of mild or moderate severity, and few subjects discontinued due to TRAEs (< 2%). The most common TRAEs were local application site reactions (oral pruritus, throat irritation, ear pruritus, and upper abdominal pain). There was no increased incidence of asthma‐related events, and no anaphylaxis or adrenaline use in the SQ HDM SLIT‐tablet group.

Conclusion

As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met. The SQ HDM SLIT‐tablet was well tolerated in a paediatric population with inadequately controlled HDM allergic asthma. Trial Registration Clinicaltrials.gov identifier: NCT03654976; EudraCT number: 2016‐004363‐39

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaSublingual ImmunotherapyPyroglyphidaeAntigens, DermatophagoidesAllergensHumansChildAdolescentMaleFemaleChild, PreschoolAnimalsTabletsDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

allergen immunotherapyallergic asthmachildrenhouse dust mitesublingual immunotherapy

Substanzen

TabletsAntigens, DermatophagoidesAllergens

Autor:innen und Institutionen

  • The David Hide Asthma and Allergy Centre, St Mary's Hospital, Newport, Isle of Wight, UK.
  • NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • University of Southampton Faculty of Medicine and University Hospital Southampton, Southampton, UK.
  • Unité d'Allergologie, Hôpital Américain de Paris, Neuilly sur Seine, France.
  • Sorbonne Université, Paris, France.
  • CRESS, Inserm, INRAE, HERA Team, Université Paris Cité, Paris, France.

ORCID-Profile: Graham Roberts, Jocelyne Just, Ole Holm Hels, Andrzej Emeryk, Carmen Vidal

Förderung

  • ALK-Abelló A/S

Zitieren

APA

Roberts, G., Just, J., Nolte, H., Hels, O. H., Emeryk, A., & Vidal, C. (2025). SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. Allergy. https://doi.org/10.1111/all.70073

Vancouver

Roberts G, Just J, Nolte H, Hels OH, Emeryk A, Vidal C. SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. Allergy. 2025. doi:10.1111/all.70073

BibTeX
@article{Roberts2025,
  author = {Roberts, Graham and Just, Jocelyne and Nolte, Hendrik and Hels, Ole Holm and Emeryk, Andrzej and Vidal, Carmen},
  title = {SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.70073}
}
Kostenlos starten →